WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 414282
CAS#: 27464-23-9 (2HCl)
Description: Oxdralazine 2HCl is the salt form of Oxdralazine, a new peripheral vasodilator, combined with propranolol and hydrochlorothiazide: a rational approach to antihypertensive treatment.
MedKoo Cat#: 414282
Name: Oxdralazine 2HCl
CAS#: 27464-23-9 (2HCl)
Chemical Formula: C8H17Cl2N5O2
Exact Mass: 285.0759
Molecular Weight: 286.16
Elemental Analysis: C, 33.58; H, 5.99; Cl, 24.78; N, 24.47; O, 11.18
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 17259-75-5 (free base); 27464-23-9 (2HCl)
Synonym: Oxdralazine 2HCl; Oxdralazine dihydrochloride; L6150; L-6150; L 6150
IUPAC/Chemical Name: Pyridazine, 3-(bis(2-hydroxyethyl)amino)-6-hydrazino-, dihydrochloride
InChi Key: UKFTXWKNVSVVCJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C8H15N5O2.2ClH/c9-10-7-1-2-8(12-11-7)13(3-5-14)4-6-15;;/h1-2,14-15H,3-6,9H2,(H,10,11);2*1H
SMILES Code: NNC1=NN=C(N(CCO)CCO)C=C1.[H]Cl.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 286.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Salvadeo A, Villa G, Segagni S, Piazza W, Criscuolo D. Comparative study of oxdralazine and dihydralazine in essential hypertension. Int J Clin Pharmacol Ther Toxicol. 1981 Aug;19(8):372-6. PMID: 7030978.
2: Salvadeo A, Villa G, Segagni S, Galli F, Criscuolo D. A crossover trial of oxdralazine in hypertension. J Clin Pharmacol. 1983 Apr;23(4):155-60. doi: 10.1002/j.1552-4604.1983.tb02719.x. PMID: 6345596.
3: Moskowitz RM, Cohn JN. Hemodynamic effects of oxdralazine and hydralazine in hypertension. Clin Pharmacol Ther. 1980 Jun;27(6):773-8. doi: 10.1038/clpt.1980.109. PMID: 7379444.
4: Salvadeo A, Villa G, Segagni S, Criscuolo D. Long-term study of oxdralazine in hypertensive patients. Arzneimittelforschung. 1979;29(11):1753-5. PMID: 396926.
5: Bartoli E, Faedda R, Arras S, Satta A, Soggia G. Oxdralazine, a new peripheral vasodilator, combined with propranolol and hydrochlorothiazide: a rational approach to antihypertensive treatment. J Clin Pharmacol. 1979 Nov- Dec;19(11-12):751-7. doi: 10.1002/j.1552-4604.1979.tb01647.x. PMID: 536472.
6: de Leeuw PW, van Soest GA, Birkenhäger WH. Aldosterone response to antihypertensive treatment. Clin Exp Hypertens A. 1982;4(9-10):1913-21. doi: 10.3109/10641968209061649. PMID: 6291819.
7: Glorioso S, Romeo B, Borsatti A, Todesco S. Valutazione clinica comparativa dell'efficacia e della tollerabilità del nuovo antiipertensivo DL 150 IT somministrato da solo ed in associazione a reserpina o propranololo [Comparative clinical evaluation of the effectiveness and tolerance of a new antihypertensive agent, DL 150 IT, administered alone and in combination with reserpine or propranolol]. Clin Ter. 1977 Nov 15;83(3):279-99. Italian. PMID: 603983.
8: Kawashima K, Watanabe TX, Sokabe H. Effect of 3-hydrazino-6[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) on renin in hypertensive rats. Jpn J Pharmacol. 1980 Feb;30(1):116-8. doi: 10.1254/jjp.30.116. PMID: 6995653.
9: Watanabe TX, Shiono K, Saito K, Sokabe H. Antihypertensive and antidiuretic effects of 3-hydrazino-6-[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) in rats. Jpn J Pharmacol. 1978 Jun;28(3):413-22. doi: 10.1254/jjp.28.413. PMID: 702944.
10: Maseri A, Pesola A, L'Abbate A, Contini C, Magini G. Systemic and coronary haemodynamic effects of the new hypotensive drug L 6150. J Int Med Res. 1976;4(6):402-9. doi: 10.1177/030006057600400605. PMID: 1027634.
